Latest News
Outlook Therapeutics, Inc.
- Outlook Therapeutics, Inc. Estimates – TRADEGATE:41O
- Outlook Therapeutics (Nasdaq:OTLK) - Stock Analysis
- Outlook Therapeutics stock costs EUR 0.44, volume 59.0 percent below average
- Two reported owners share voting power over a stake above 5% in Outlook Therapeutics (OTLK).
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
- Certain Common Stock of Outlook Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-OCT-2026.
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Offi
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer Ahead of LYTENAVA U.S. Launch
- Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
- Outlook Therapeutics names Greg DiPasquale as chief commercial officer By Investing.com
- Outlook Therapeutics Submits HCPCS Level II Application to
- Outlook Therapeutics applies for permanent J-code for LYTENAVA
Headlines from the last 30 days, linking to the original publishers. See all market news →